GSK’s adjuvanted vax beats Baxter shot
In a head-to-head trial of swine flu vaccines, GlaxoSmithKline’s (NYSE: GSK) adjuvanted shot outperformed the traditional version from Baxter ( NYSE: BAX ). Children given GSK’s Pandemrix–which contained an adjuvant known as AS03–developed a stronger immune response that those who received Baxter’s Celvapan. The difference was most pronounced in children ages
